The association of body mass index and prostate-specific antigen in a population-based study.

Recent studies of men with prostate carcinoma suggest that obesity may be associated with more advanced-stage disease and lower overall survival rates. One possible link between body mass index (BMI) and prostate carcinoma prognosis may be disease ascertainment. Prostate-specific antigen (PSA) is widely used to screen for prostate carcinoma.

The authors examined the association between BMI and PSA in a population-based study of 2779 men without prostate carcinoma. Between 2001 and 2004, these men were enrolled in a study sponsored by the San Antonio Center of Biomarkers of Risk, a clinical and epidemiologic center of the Early Detection Research Network of the National Cancer Institute.

The mean PSA value decreased in a linear fashion with an increase in BMI category, from 1.01 ng/mL in normal weight men to 0.69 ng/mL in obese (Class III) men, after adjusting for race/ethnicity and age.

Lower levels of PSA in obese and overweight men could mask biologically consequential prostate carcinoma.

Baillargeon J, Basler J, Bradshaw P, Hernandez J, Higgins B, Kristal AR, Lynch S, Pollock BH, Rozanski T, Thompson I, Troyer D


Cancer, 2005, 103 (5)

Version 5.1.0